

Article

# Expanding Genotype/Phenotype Correlation in 2p11.2-p12 Microdeletion Syndrome

Alessandra Ferrario <sup>1</sup>, Nijas Aliu <sup>2</sup>, Claudine Rieubland <sup>2</sup>, Sébastien Vuilleumier <sup>1</sup>, Hilary M. Grabe <sup>1</sup> and Pascal Escher <sup>1,3,\*</sup>

<sup>1</sup> Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; alessandra.ferrario@students.unibe.ch (A.F.); sebastien.vuilleumier@insel.ch (S.V.); hilary.grabe@insel.ch (H.M.G.)

<sup>2</sup> Department of Human Genetics, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; nijas.aliu@insel.ch (N.A.)

<sup>3</sup> Department of BioMedical Research, University of Bern, 3010 Bern, Switzerland

\* Correspondence: pascal.escher@insel.ch

**Abstract:** Chromosomal abnormalities on the short arm of chromosome 2 in the region p11.2 have been associated with developmental delay, intellectual disability, facial anomalies, abnormal ears, skeletal and genital malformations. Here we describe a patient with a de novo interstitial heterozygous microdeletion on the short arm of chromosome 2 in the region p11.2-p12. He presents with facial dysmorphism characterized by a broad and low root of the nose and low-set protruding ears. Clinical examinations during follow-up visits revealed congenital pendular nystagmus, decreased visual acuity and psychomotor development disorder including intellectual disability. The heterozygous 5 Mb-microdeletion was characterized by an array CGH (Comparative Genomic Hybridization) analysis. In the past two decades, nine patients with microdeletions in this region have been identified by array CGH analysis and were reported in the literature. All these patients show psychomotor development disorder and outer and/or inner ear anomalies. In addition, most of the patients have mild to severe intellectual disability and show facial malformations. We reviewed the literature on PubMed and OMIM using the gene/loci names as search terms in an attempt to identify correlations between genes located within the heterozygous microdeletion and the clinical phenotype of the patient, in order to define a recognizable phenotype for the 2p11.2p12 microdeletion syndrome. We discuss additional symptoms that are not systematically present in all patients and contribute to a heterogeneous clinical presentation of this microdeletion syndrome.

**Keywords:** microdeletion; chromosome 2; neurodevelopmental disorder; facial malformations; congenital ear anomalies; *POLR1A*; *REEP1*; *ELMOD3*; *FOXI3*



**Citation:** Ferrario, A.; Aliu, N.; Rieubland, C.; Vuilleumier, S.; Grabe, H.M.; Escher, P. Expanding Genotype/Phenotype Correlation in 2p11.2-p12 Microdeletion Syndrome. *Genes* **2023**, *14*, 2222. <https://doi.org/10.3390/genes14122222>

Academic Editor: Maria Piccione

Received: 30 October 2023

Revised: 12 December 2023

Accepted: 14 December 2023

Published: 16 December 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Chromosomal abnormalities often affect multiple organ systems [1]. These are rare events, but the more individuals with a similar phenotype are described in the literature, the better a genetic disease can be characterized by a recognizable phenotype, despite heterogeneous clinical presentation and variable penetrance [2]. So far, nine patients with an interstitial heterozygous microdeletion on the short arm of chromosome 2 in the region p11.2-p12 have been identified by array CGH (Comparative Genomic Hybridization) analysis [3–10]. The first reported case with an interstitial microdeletion located in 2p11.2-p12 described a 5-year-old boy with microcephaly, a high forehead, broad high nasal bridge, ear anomalies, feet and digital anomalies, delayed psychomotor development, intellectual disability and speech delay [3]. A second patient was described shortly thereafter as having the following common characteristics: a similar facial dysmorphism, delayed motor development, intellectual disability and speech delay. Additionally, the patient was affected

by ataxia and a congenital vesicoureteral reflux [4]. In a third case with a similar chromosomal microdeletion, ear anomalies, a high forehead, broad high nasal bridge, delayed psychomotor development and delayed speech progression were reported, and, for the first time, hearing impairment [5]. Four additional patients with overlapping interstitial microdeletions in 2p11.2-p12 all had ear anomalies [6–8]. Three patients also showed facial dysmorphism and were diagnosed with psychomotor development delay [6,8]. Because the fourth patient was described at the age of 4 months, the development progress could not be evaluated properly [7]. This young patient was, however, the first one not showing facial malformations, but showed left aural atresia and ipsilateral internal carotid artery agenesis [7]. An additional patient also presented with ear anomalies, facial dysmorphism, speech delay and delayed psychomotor development [10]. This patient is the only one described as an adult, at the age of 35 years, when she developed an atypical early-onset parkinsonism [10]. Finally, a patient with a homozygous 25 kb microdeletion spanning the *ELMOD3*, *CAPG* and *SH2D6* genes was reported [9].

Here we describe another patient with a de novo interstitial chromosomal 2p11.2-p12 heterozygous microdeletion characterized by array CGH analysis. To understand the function of the genes affected by the microdeletion in our patient, the literature on PubMed and OMIM was reviewed using each gene name as a search term. We discuss this literature review in light of the clinical symptoms present in patients harboring 2p11.2-p12 microdeletions and in an attempt to establish genotype–phenotype correlations.

## 2. Materials and Methods

### 2.1. Study Design

All aspects of this retrospective study adhered to the tenets of the Declaration of Helsinki. The patient was recruited from the Inselspital, Bern University Hospital, Bern, Switzerland. The study was conducted in accordance with the Swiss Human Research Act and the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines of Good Clinical Practice (GCP). Written informed consent was given by the parents of the patient for the scientific use of clinical and molecular genetic data. We performed a medical record review. The mother of the patient provided further information. The photographs of Figure 1 were prepared in close collaboration with the mother of the proband. An additional written consent for the use of these photographs was obtained from the parents. Additional patients discussed in this article were all previously published.

### 2.2. Molecular Genetic Analysis

For standard karyotyping, peripheral blood lymphocytes were extracted from heparin blood and cultivated. GTG (G-bands after trypsin and Giemsa) banding was performed at an ISCN (International System for Human Cytogenetic Nomenclature) quality of 550 bands on metaphase chromosomes of 10 cells. Parental DNA was further analyzed by fluorescence in situ hybridization (FISH) using whole chromosome painting for chromosome 2 (WCP-2; Q-Biogene; Heidelberg, Germany). Molecular karyotyping was performed by array CGH analysis using the 4x135k PerkinElmer CGX-Array (PerkinElmer, Waltham, MA, USA). DNA was isolated from peripheral blood lymphocytes using the Qiagen Maxi-Kit (Qiagen, Hilden, Germany). Bioinformatic analysis was based on the human reference genome hg18, build 36, and performed with Genoglyphix 3.0 software (PerkinElmer). Additionally, the chromosomal region 15q11 was analyzed by MLPA (multiplex ligation dependent Probe Amplification) for deletions, duplications and methylation using ME028-B2 test (MRC Holland, Amsterdam, The Netherlands).

### 2.3. Literature Search

OMIM (Online Mendelian Inheritance in Man) and PubMed databases were, respectively, accessed at <https://www.omim.org/> and <https://pubmed.ncbi.nlm.nih.gov/> from 10 August 2021 to 01 May 2023. We used ‘official HGNC (Human Genome Nomenclature

Committee) gene symbol' as the search term in OMIM. On PubMed we used 'official HGNC gene symbol AND eye' as search term.

### 3. Results

#### 3.1. Clinical Case Report

We describe the first child of a healthy, non-consanguineous Swiss–Kosovan couple. The patient is presently 12 years old (Figure 1). He has a 4-year-old younger, unaffected sister. The patient had his initial visits in the Inselspital, Bern University Hospital, Bern, Switzerland with continued periodic follow-up examinations there.

The mother, then aged 22 years, gave birth after an uncomplicated pregnancy with vaginal delivery at term. The boy had a birth weight of 2540 g (1–2th centile), a head circumference of 32 cm (<1th centile) and a birth length of 47 cm (1–2th centile). Apgar score was 8, 9 and 10 at 1, 5 and 10 min respectively. He was born with a bilateral syndactyly of toes II/III and facial dysmorphism including a flat midface, broad and low nasal root, narrow lips, low-set protruding ears and downslanting palpebral fissures. After birth, the first clinical concerns were episodes of cyanosis during feeding and the inability to drink due to hypotension of the oropharyngeal muscles. Later, a muscular hypotension of shoulder and torso muscles was diagnosed and resulted in delayed motor development (sitting without support at 11 months, walking alone at 22 months) and difficulties in coordination and fine motor skills. Further assessments revealed delayed cognitive skills and a development quotient of 64 to 86 over time. Speech progression was normal under speech therapy. Hearing assessment and brain MRI were normal.



**Figure 1.** Facial images of the described patient at the age of 12 years. The side view (**left panel**) shows the low-set protruding ears. The front view (**right panel**) shows the broad and low root of the nose, the sloping eyelid axis and ocular torticollis.

An ophthalmological examination at the age of 4 months showed a horizontal pendular nystagmus to the left and high-degree visual impairment. Visual impairment was thought to be secondary to possible optic atrophy, but given the patient's age and nystagmus a conclusive examination of the optic nerve was not possible at this time. Ophthalmological follow-up examinations at the age of 4, 6 and 8 years showed the persistence of the horizontal pendular nystagmus. Ocular alignment was orthophor. In addition, ocular torticollis (left-hand turn of 30° and tilt to the right) and astigmatism were evident. At the most recent follow-up visit at the age of 12 years, the pendular nystagmus and the ocular torticollis had remained stable. The anterior and posterior segments were normal, including the optic nerve head. Importantly, the distance visual acuity had markedly improved (Table 1).


**Table 1.** Distant and near visual acuity of binocular vision (OU), monocular vision of the left eye (OS) and monocular vision of the right eye (OD) at age 4, 6, 8 and 12 years.

| Age (years)            | 4        | 6                   | 8                    | 12                 |
|------------------------|----------|---------------------|----------------------|--------------------|
| Distance visual acuity | OU: 0.63 | OD: 0.16<br>OS: 0.2 | OD: 0.5<br>OS: 0.63  | OU: 1.0            |
| Near visual acuity     | OU: 0.5  | OD: 0.16            | OD: 0.63<br>OS: 0.25 | OD: 0.4<br>OS: 0.5 |

The patient has a friendly and helpful disposition and good social skills without behavioral disturbances. He profits from support in a special school and shows high interest in social activities, playing with his healthy younger sister and in making intellectual progress.


### 3.2. Genetic Analysis

Upon genetic counselling of the parents, genetic analyses were initiated at the age of 2 years. Karyotyping by GTG banding identified an interstitial chromosomal 2p11.2 heterozygous microdeletion (Figure 2). Karyotyping by GTG banding of the parents did not reveal any chromosomal abnormalities. A detailed FISH analysis of parental chromosomes 2 did not identify any chromosomal abnormalities neither. Taken together, these chromosomal analyses indicated that the heterozygous microdeletion had appeared de novo in the patient. Angelman Syndrome was excluded by detailed analysis of the patient's chromosomal region 15q11.



**Figure 2.** Karyotyping of the proband by standard GTG banding identified a 46,XY,del(2)(p11.2p11.2) karyotype.

The array CGH analysis then revealed an interstitial heterozygous microdeletion of 5 Mb on the short arm of chromosome 2 at p11.2. The deletion located close to the centromere spanned from position 83,836,581 to position 88,835,028 according to UCSC genome browser assembly GRCh36/hg18: arr[hg18] 2p11.2(83,836,581\_88,835,028)x1 (Figure 3).



**Figure 3.** Array CGH analysis showing the heterozygous interstitial microdeletion arr[hg18]2p11.2(83,836,581\_88,835,028)x1 in detail. The 2p11.2 chromosomal region (top row, red box) is enlarged to show in detail (from top to down): probe array signals (black dots) with heterozygously deleted region (shaded in blue); sequence gaps (green, orange); deleted genes and loci (gray, blue, light blue). This image has been extracted from [www.genoglyphix.com](http://www.genoglyphix.com) (PerkinEmer).

This region harbors 46 protein-coding genes, three pseudogenes, eight microRNAs, five other RNAs (nucleolar, non-coding, anti-sense) and five undescribed loci (Table 2).

**Table 2.** List of loci identified within the interstitial chromosomal 2p11.2 microdeletion. The region is described from 5' to 3'. Gene: official HGNC gene symbols; gene product: full gene or protein name; inheritance: autosomal dominant (AD), autosomal recessive (AR); disease: gene-associated human diseases; OMIM (Online Mendelian Inheritance in Man) numbers are listed. In bold, genes for which autosomal dominant inheritance has been reported.

| Gene                | Gene Product  | Inheritance | Disease                                | OMIM   |
|---------------------|---|-------------|--|--------|
| <i>FUNDC2P2</i>     | FUN14 domain containing 2 pseudogene 2                  |             |  |        |
| <i>SUCLG1</i>       | Succinate-CoA Ligase, GDP/ADP-forming, $\alpha$ subunit | AR          | Mitochondrial DNA depletion syndrome 9 | 245400 |
| <i>DNAH6</i>        | Dynein, axonemal, heavy chain 6                         |             |  |        |
| <i>TRABD2A</i>      | TRAB domain-containing protein 2a                       |             |  |        |
| <i>TMSB10</i>       | Thymosin, $\beta$ -10                                   |             |  |        |
| <i>KCMF1</i>        | Potassium channel modulatory factor 1                   |             |  |        |
| <i>LINC01964</i>    | Long intergenic non-protein coding RNA 1964             |             |  |        |
| <i>TCF7L1-IT1</i>   | TCF7L1 intronic transcript 1                            |             |  |        |
| <i>TCF7L1</i>       | Transcription factor 7-like 1                           |             |  |        |
| <i>LOC102724579</i> |   |             |  |        |
| <i>TGOLN2</i>       | Trans-Golgi network protein 2                           |             |  |        |
| <i>RETSAT</i>       | Retinol saturase  |             |  |        |

Table 2. Cont.

| Gene          | Gene Product   | Inheritance     | Disease   | OMIM                                     |
|---------------|--|-----------------|---|--|
| <b>ELMOD3</b> | <b>ELMO/CED12 domain-containing protein 3</b>              | <b>AD</b><br>AR | <b>Deafness 81</b><br>Deafness 88   | <b>619500</b><br>615429                  |
| CAPG          | Capping protein, gelsolin-like                             |                 |   |  |
| SH2D6         | SH2 domain containing 6                                    |                 |   |  |
| PARTICL       | Promoter of MAT2 AS radiation-induced circulating lncRNA   |                 |   |  |
| MAT2A         | Methionine adenosyltransferase 2A                          |                 |   |  |
| GGCX          | $\gamma$ -glutamyl carboxylase                             | AR              | Combined deficiency of Vitamin K-dependent clotting factors<br>Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency | 277450<br>610842                         |
| VAMP8         | Vesicle-associated membrane protein 8                      |                 |   |  |
| VAMP5         | Vesicle-associated membrane protein 5                      |                 |   |  |
| RNF181        | Ring finger protein 181                                    |                 |   |  |
| TMEM150A      | Transmembrane protein 150a                                 |                 |   |  |
| USP39         | Ubiquitin-specific protease 39                             |                 |   |  |
| C2ORF68       | Chromosome 2 open reading frame 68                         |                 |   |  |
| SFTPB         | Surfactant protein B                                       | AR              | Pulmonary surfactant metabolism dysfunction 1   | 265120                                   |
| GNLY          | Granulysin   |                 |   |  |
| ATOH8         | Atonal-homolog 8   |                 |   |  |
| MIR6071       | MicroRNA 6071  |                 |   |  |
| LOC284950     |  |                 |   |  |
| ST3GAL5       | ST3 $\beta$ -galactoside $\alpha$ -2,3-sialyltransferase 5 | AR              | Salt and pepper developmental regression syndrome   | 609056                                   |
| ST3GAL5-AS1   | ST3GAL5 antisense RNA 1                                    |                 |   |  |
| <b>POLR1A</b> | <b>RNA polymerase I subunit A</b>                          | <b>AD</b>       | <b>Acrofacial dysostosis, Cincinnati type</b>   | <b>616462</b>                            |
| PTCD3         | Pentatricopeptide repeat domain 3                          | AR              | Combined oxidative phosphorylation deficiency 51  | 619057                                   |
| SNORD94       | Small nucleolar RNA, C/D box 94                            |                 |   |  |
| IMMT          | Inner membrane mitochondrial protein                       |                 |   |  |
| MIR4779       | MicroRNA 4779  |                 |   |  |
| MRPL35        | Mitochondrial ribosomal protein L35                        |                 |   |  |
| <b>REEP1</b>  | <b>Receptor expression-enhancing protein 1</b>             | <b>AD</b><br>AR | <b>Spastic paraplegia 31</b><br><b>Distal hereditary motor neuronopathy 12</b><br>Distal hereditary motor neuronopathy 6                          | <b>610250</b><br><b>614751</b><br>620011 |
| KDM3A         | Lysine-specific demethylase 3a                             |                 |   |  |
| CHMP3         | Charged multivesicular body protein 3                      |                 |   |  |
| RNF103        | Ring finger protein 103                                    |                 |   |  |
| RMND5A        | Required for meiotic nuclear division 5 homolog a          |                 |   |  |
| CD8A          | CD8 antigen, $\alpha$ polypeptide                          | AR              | Familial CD8 deficiency   | 608957                                   |
| CD8B          | CD8 antigen, $\beta$ polypeptide                           |                 |   |  |
| ANAPC1P1      | ANAPC1 pseudogene 1  |                 |   |  |



Table 2. Cont.

| Gene                | Gene Product   | Inheritance  | Disease                                 | OMIM          |
|---------------------|--|--------------|---|---------------|
| <i>RGPD1</i>        | RANBP2 like and GRIP domain containing 1                     |              |   |               |
| <i>RGPD2</i>        | RANBP2 like and GRIP domain containing 2                     |              |   |               |
| <i>PLGLB2</i>       | Plasminogen like B2  |              |   |               |
| <i>PLGLB1</i>       | Plasminogen like B1  |              |   |               |
| <i>LOC285074</i>    |  |              |   |               |
| <i>MIR4771-2</i>    | MicroRNA 4771-2  |              |   |               |
| <i>MIR4772-1</i>    | MicroRNA 4771-1  |              |   |               |
| <i>CYTOR</i>        | Cytoskeleton regulator RNA                                   |              |   |               |
| <i>MIR4435-1</i>    | MicroRNA 4435-1  |              |   |               |
| <i>MIR4435-2</i>    | MicroRNA 4435-2  |              |   |               |
| <i>KRCC1</i>        | Lysine rich coiled-coil 1                                    |              |   |               |
| <i>FABP1</i>        | Fatty acid binding protein 1                                 |              |   |               |
| <i>SMYD1</i>        | SET and MYND domain-containing protein 1                     |              |   |               |
| <i>MIR4780</i>      | MicroRNA 4780  |              |   |               |
| <i>THNSL2</i>       | Threonine synthase like 2                                    |              |   |               |
| <b><i>FOXI3</i></b> | <b>Forkhead box I3</b>                                       | <b>AD/AR</b> | <b>Craniofacial microsomia 2</b>        | <b>620444</b> |
| <i>TEX37</i>        | Sperm microtubule inner protein 9                            |              |   |               |
| <i>LOC101928371</i> |  |              |   |               |
| <i>EIF2AK3</i>      | Eukaryotic translation initiation factor 2 $\alpha$ kinase 3 | AR           | Wolcott–Rallison syndrome               | 226980        |
| <i>LOC101928403</i> |  |              |   |               |
| <i>RP1A</i>         | Ribose 5-phosphate isomerase A                               | AR           | Ribose 5-phosphate isomerase deficiency | 608611        |
| <i>ANKRD36BP2</i>   | Ankyrin repeat domain 36B pseudogene 2                       |              |   |               |
| <i>MIR4436A</i>     | MicroRNA 4436a   |              |   |               |

### 3.3. Literature Search

To identify disease-associated genes within the deleted region, we searched the literature on the OMIM (Online Mendelian Inheritance in Man) and PubMed databases by using the ‘gene name’ as the search term. To search for eye-specific data pertinent to decreased visual acuity and nystagmus, an additional search was performed on PubMed using the search term ‘gene name AND eye’. We accessed OMIM and PubMed from 10.08.2021 to 01.05.2023.

According to OMIM, 12 out of the 46 protein-coding genes have been associated with human disease (*SUCLG1*, *ELMOD3*, *GGCX*, *SFTPB*, *ST3GAL5*, *POLR1A*, *PTCD3*, *REEP1*, *CD8A*, *FOXI3*, *EIF2AK3*, *RP1A*) (Table 2). For eight genes (*SUCLG1*, *GGCX*, *SFTPB*, *ST3GAL5*, *PTCD3*, *CD8A*, *EIF2AK3*, *RP1A*), autosomal recessive inheritance has been established. These genes are therefore unlikely to contribute to the clinical phenotype. Both recessive and dominant inheritance has been associated with *ELMOD3* and *FOXI3*. For *POLR1A* and *REEP1*, autosomal dominant inheritance with loss-of-function as a disease mechanism has been reported.

## 4. Discussion

To better define the symptoms from the clinical findings present in our patient, we reviewed all above-mentioned patients with interstitial chromosomal 2p11.2-p12 microdeletions characterized by array CGH analysis [3–10]. We report the published clinical symptoms and the exact genomic localization for all patients (Table 3).

**Table 3.** Synoptic overview of microdeletion, patient data and clinical symptoms of all currently known patients with microdeletions in the genomic region 2p11.2p12. M: male; F: female; y: year; m: month; +: present; (+): subtle; -: absent; n.a.: not available.


| Patient No.<br>Reference        | 1<br>Tzschach et al.,<br>2009 [3] | 2<br>Witzl et al.,<br>2009 [4] | 3<br>Rocca et al.,<br>2012 [5] | 4<br>Stevens et al.,<br>2015 [6] | 5<br>Stevens et al.,<br>2015 [6] | 6<br>Silipigni et al.,<br>2015 [8] | 7<br>Baviera-Munoz<br>et al., 2021 [10] | 8<br>Lahbib et al.,<br>2019 [9] | 9<br>Tassano et al.,<br>2015 [7] | 10<br>Present Case        |
|---------------------------------|-----------------------------------|--------------------------------|--------------------------------|----------------------------------|----------------------------------|------------------------------------|---|---------------------------------|----------------------------------|---------------------------|
| Position in 2p                  | p11.2p12                          | p11.2p12                       | p11.2p12                       | p11.2p12                         | p11.2p12                         | p11.2p12                           | p11.2                                   | p11.2                           | p11.2                            | p11.2                     |
| Deletion size                   | 11.4 Mb                           | 10.4 Mb                        | 9.2 Mb                         | 9.4 Mb                           | 9.4 Mb                           | 9.4 Mb                             | 3.9 Mb                                  | 25.09 kb                        | 2.4 Mb                           | 5.0 Mb                    |
| Genomic<br>Localization         | 79,902,77–<br>91,304,813          | 76,796,317–<br>87,229,788      | 77,763,071–<br>87,175,553      | 77,760,623–<br>87,184,476        | 77,760,623–<br>87,184,476        | 77,772,931–<br>87,178,871          | 83,188,936–<br>87,125,435               | 85,468,519–<br>85,493,609       | 87,571,956–<br>89,902,424        | 83,836,581–<br>88,835,025 |
| Sex                             | F                                 | M                              | F                              | M                                | M                                | F                                  | F                                       | M                               | F                                | M                         |
| Inheritance                     | de novo                           | de novo                        | de novo                        | de novo                          | de novo                          | de novo                            | de novo                                 | parental,<br>homozygous         | paternal                         | de novo                   |
| Age evaluation                  | 5 y                               | 5 y 9 m                        | 9 y                            | 15 y 8 m                         | 5 y 4 m                          | 12 m                               | 35 y                                    | 7 y                             | 4 m                              | 11 y 9 m                  |
| Microcephaly                    | +                                 | -                              | -                              | -                                | -                                | -                                  | -                                       | -                               | -                                | -                         |
| High forehead                   | +                                 | +                              | +                              | +                                | +                                | +                                  | +                                       | -                               | -                                | -                         |
| Broad high<br>nasal bridge      | +                                 | +                              | +                              | +                                | +                                | +                                  | (+)                                     | -                               | -                                | +                         |
| Ear anomalies                   | +                                 | +                              | +                              | +                                | +                                | +                                  | +                                       | +                               | +                                | +                         |
| Feet anomalies                  | +                                 | +                              | -                              | +                                | -                                | -                                  | -                                       | -                               | -                                | +                         |
| Digital<br>anomalies            | +                                 | +                              | -                              | -                                | -                                | -                                  | -                                       | -                               | -                                | -                         |
| Growth<br>retardation           | +                                 | +                              | +                              | -                                | -                                | -                                  | +                                       | -                               | -                                | -                         |
| Speech delay                    | +                                 | +                              | +                              | +                                | +                                | n.a.                               | -                                       | +                               | n.a.                             | -                         |
| Delayed<br>motor<br>development | +                                 | +                              | +                              | +                                | +                                | +                                  | +                                       | +                               | -                                | +                         |
| Hypertonia                      | -                                 | +                              | -                              | hypotonia                        | -                                | -                                  | -                                       | hypotonia                       | -                                | hypotonia                 |
| Ataxia                          | -                                 | +                              | +                              | -                                | -                                | -                                  | -                                       | -                               | -                                | -                         |
| Intellectual<br>disability      | +                                 | mild                           | mild                           | moderate                         | borderline                       | mild                               | -                                       | +                               | ?                                | +                         |
| Happy<br>disposition            | +                                 | +                              | -                              | +                                | +                                | +                                  | ?                                       | -                               | ?                                | +                         |



Table 3. Cont.

| Patient No.<br>Reference | 1<br>Tzschach et al.,<br>2009 [3] | 2<br>Writzl et al.,<br>2009 [4] | 3<br>Rocca et al.,<br>2012 [5]                                      | 4<br>Stevens et al.,<br>2015 [6]                | 5<br>Stevens et al.,<br>2015 [6] | 6<br>Silipigni et al.,<br>2015 [8]                    | 7<br>Baviera-Munoz<br>et al., 2021 [10]   | 8<br>Lahbib et al.,<br>2019 [9]                       | 9<br>Tassano et al.,<br>2015 [7]  | 10<br>Present Case                                    |
|--------------------------|-----------------------------------|---------------------------------|---|---|----------------------------------|---|---|---|---|---|
| Other<br>symptoms        | single umbilical<br>artery        | vesico-ureteral<br>reflux       | incomplete<br>myelination<br>white matter,<br>hearing<br>impairment | hyperreflexia of<br>lower limbs,<br>clumsy gait | hypermobile<br>hands             | bilateral choanal<br>atresia, atrial<br>septal defect | atypical<br>early-onset<br>parkinsonsim<br>with dystonia<br>and lower limb<br>spasticity,<br>scoliosis,<br>strabismus,<br>amblyopia | autism, hearing<br>impairment,<br>primary<br>enuresis | congenital aural<br>atresia, agenesis<br>of internal<br>carotid artery,<br>velopharyngeal<br>insufficiency,<br>aberrant course<br>of left facial<br>nerve, microtia,<br>hearing<br>impairment | pendular<br>horizontal<br>nystagmus,<br>visual acuity |

To better visualize the microdeletions of the 10 patients and overlapping deleted regions, we generated a synoptic view of the available array CGH data (Figure 4).



**Figure 4.** Overview of the deleted regions in the previously reported patients and the patient described in this article. The numbers mark the position on chromosome 2 at the band 2p11.2p12 according to UCSC genome browser assembly GRCh36/hg18. On the right side, patients are numbered according to Table 3.

Diseases with autosomal dominant inheritance have been linked to four genes located on the heterozygously deleted chromosomal region: *POLR1A*, *ELMOD3*, *FOXI3* and *REEP1*.

All 10 patients mentioned above show abnormalities in the formation of the outer and/or the inner ear. With the exception of patients 8 and 9, the deleted genomic regions contain in all patients the *POLR1A* gene coding for the 194-kD  $\alpha$  subunit of the RNA polymerase 1 (OMIM #616404). Pathogenic heterozygous variants in *POLR1A* are associated with acrofacial dysostosis, Cincinnati type, the symptoms of which include large and low-set ears, downslanting palpebral fissures, an underdeveloped midface, micrognathia, decreased head circumference and short stature [11,12]. Haploinsufficiency in *POLR1A*, as present in our patient with a heterozygous 2p11.2 microdeletion, may therefore be the genetic cause of the large and low-set ears (Figure 1), and contribute to the observed downslanting palpebral fissures and facial dysmorphism with flat midface.

In patient 8, the small 25 kb homozygous deletion affects only three genes, *ELMOD3*, *CAPG* and *SH2D6* [9]. Based on the reported autosomal recessive inheritance in a consanguineous Pakistani family affected with non-syndromic deafness (DFNB88; OMIM #615429) [13], hearing loss was attributed to the homozygous deletion of *ELMOD3* in this patient. Because hearing loss is not reported in the patients with a heterozygous deletion of *ELMOD3*, except for patient 3, the disease mechanism in a three-generation Chinese pedigree reported with *ELMOD3*-linked autosomal dominant non-syndromic deafness (DNFA81; OMIM #619500) may involve dominant-negative effects rather than haploinsufficiency [14–16]. Large ears are also reported in patient 8 [9], and a contribution to the external ear phenotype of one of three genes *ELMOD3*, *CAPG* and *SH2D6* cannot be excluded.

In contrast to the other patients with reported large ears, microtia is reported in patient 9 [7]. Consistently, *POLR1A* is not deleted in this patient. The heterozygous microdeletion harbors the *FOXI3* gene, coding for the transcription factor forkhead box I3, involved in the development of teeth, hair and the inner ear (OMIM #612351) (Figure 4). Recently, heterozygous pathogenic variants in *FOXI3* have been associated with craniofacial microsomia, also known as Goldenhar syndrome, whose cardinal symptoms are microtia and craniofacial microsomia [17,18]. Our patient 10 is the only one among the reported patients in which both *POLR1A* and *FOXI3* are deleted. Based on the clinical symptoms of our patient with large and low-set ears (Figure 1), one might hypothesize that haploinsufficiency of *POLR1A* overrides that of *FOXI3* during ear development. Additionally,

haploinsufficiency is not the sole disease mechanism in *FOXI3*-linked microtia, as recessive inheritance has been demonstrated in a consanguineous Pakistani family [17].

*REEP1* encodes the receptor expression-enhancing protein 1. Heterozygous pathogenic deletions, frameshift, splice-site, missense and 3'-UTR variants cause hereditary spastic paraplegia type 31 (SPG31) [19] and a splice-site variant hereditary motor neuropathy 12 (HMND12; OMIM 614751) [20]. All these variants may eventually lead to haploinsufficiency [19]. SPG31 is a pure hereditary spastic paraplegia leading to progressive spasticity of the lower limbs, with a rare complication of peripheral nerve involvement [21–23]. Initial symptoms in SPG31 patients appear in a bimodal pattern, before the age of 20 years or after the age of 30 years, and penetrance is incomplete even at an advanced age [21]. Strikingly, patient 7 is the only adult patient reported so far and her clinical symptoms of an atypical early onset parkinsonism include dystonia and lower limb spasticity [10]. Based on this report, neurological follow-up examinations of our patient will include nerve conduction studies.

Only our patient and patient 7 [10] have ocular anomalies, such as strabismus, amblyopia, decreased visual acuity and nystagmus (Table 3). These two patients share the most similar interstitial microdeletion (Figure 4). The improvement in distance visual acuity observed in our patient is remarkable. The medical history of patient 7 also mentions amblyopia, but no decrease in visual acuity is reported at age 35 years [10], suggesting a similar positive development in visual acuity for this patient.

Shared heterozygous deleted genes for which expression in the eye has been reported include *TRABD2A*, *TMSB10*, *RETSAT*, *MAT2A*, *GGCX*, *ST3GAL5*, *PTCD3*, *RPIA*. *TRABD2A* encodes the 505-aa TIKI1 protein, a negative regulator of Wnt signaling during embryonic development of the eye [24]. *TMSB10* encodes thymosin  $\beta$ -10 expressed during early human retinogenesis [25]. *RETSAT* encodes the retinol saturase catalyzing the saturation of all-trans-retinol to dihydroretinoid metabolites [26]. This process is not involved in the vitamin A cycle of the visual system, but in the absence of retinol saturase, mice are prone to adiposity [26]. *MAT2A* encodes the catalytic part of the methionine adenosyltransferase 2, catalyzing the synthesis of the methyl donor S-adenosylmethionine (SAM). Its expression is upregulated during the acute phase after brain, retinal and spinal cord injury [27]. No specific disease has been associated so far with defects in *TRABD2A*, *TMSB10*, *RETSAT* and *MAT2A*. Homozygous or compound heterozygous pathogenic variants in *GGCX* are associated with a pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency (OMIM #610842) and the combined deficiency of the vitamin K-dependent clotting factor (OMIM #277450). A single patient is described with motor ataxia of the eye [28], but this pseudoxanthoma elasticum-like disorder also affects the optic nerve and the retina [29]. Given that exclusively autosomal recessive inheritance has been reported, a heterozygous deletion of *GGCX* is unlikely to contribute to the clinical phenotype in these two patients. *ST3GAL5* encodes the ST3  $\beta$ -galactoside  $\alpha$ -2,3-silyltransferase 5. This enzyme catalyzes the first step of the synthesis of several different gangliosides (OMIM #604402). Homozygous or compound heterozygous pathogenic variants in *ST3GAL5* cause the salt and pepper developmental regression syndrome (MIM #609056). *PTCD3* encodes the pentatricopeptide repeat domain-containing protein 3, which is essential for translation in mitochondria (MIM #614918). Homozygous and compound heterozygous pathogenic variants in *PTCD3* cause the combined oxidative phosphorylation deficiency 51 (COXPD51), for which symptoms include respiratory insufficiency, nystagmus, delayed psychomotor development, brain lesions, bilateral hearing loss, and optic atrophy (OMIM #619057) [30]. *RPIA* encodes ribose 5-phosphate isomerase A, an enzyme of the pentose phosphate pathway (OMIM #180430). Homozygous and compound heterozygous pathogenic variants in *RPIA* cause ribose 5-phosphate isomerase deficiency (RPIAD; OMIM #608611). In a cohort of four patients, development delay, speech delay and alterations in cerebral white matter were always present, and ocular phenotypes included optic atrophy in one patient, exotropia and retinitis pigmentosa in the others [31]. Again, only autosomal recessive inheritance has been reported for *ST3GAL5*, *PTCD3* and *RPIA*.

Our patient suffers from muscular hypotension of shoulder and torso muscles. Patient 4 is described to have a hypotonic habitus, which is absent in patient 5, despite them harboring an identical microdeletion to patient 4 [6]. This suggests that either the microdeletion is not responsible for this phenotype or that only compound heterozygous mutations in the overlapping region are causative. Our literature search identified no correlation between genomic defects in the mentioned region and muscular hypotension.

Of note, only in patients 1 and 9 is the malformation of vessels reported [3,7]. The microdeletion in these two patients spans further from the centromere compared to the other deletions listed in Figure 4. This could suggest that deletions between 88'835,025 and 91,304,813 have an impact on the formation of vessels. A literature review of the affected genes could help to support this statement.

In conclusion, the heterozygous deletion of *POLR1A* may contribute most to the clinical phenotype in interstitial chromosomal 2p11.2p12 microdeletions, causing large and low-set ears, downslanting palpebral fissures and facial dysmorphism with flat midface. Importantly, follow-up examinations of patients with heterozygous *REEP1* deletion should include specific neurological tests to assess spasticity of the lower limbs and peripheral nerve involvement, and this should carry on through adulthood.

Fortunately, the patient newly reported here has shown a satisfactory visual development. The collaboration between the ophthalmologists and neuro-pediatricians at our hospital and the special school addressing visual and intellectual support he needs continues on a regular schedule. This is part of the multidisciplinary care typically needed for patients with chromosomal abnormalities. Genetic counselling and analysis is a cornerstone of this comprehensive care and could be initiated early in life, thanks to supportive parents.

**Author Contributions:** Conceptualization, A.F. and P.E.; methodology, A.F., N.A. and P.E.; software, validation, A.F., N.A. and P.E.; formal analysis, A.F. and P.E.; investigation, A.F., N.A., C.R., S.V., H.M.G. and P.E.; resources, P.E.; data curation, A.F. and P.E.; writing—original draft preparation, A.F. and P.E.; writing—review and editing, A.F., N.A., C.R., S.V., H.M.G. and P.E.; visualization, A.F., N.A., C.R., S.V., H.M.G. and P.E.; supervision, P.E.; project administration, P.E. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** All aspects of this retrospective study adhered to the tenets of the Declaration of Helsinki. The study was conducted in accordance with the Swiss Human Research Act and the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines of Good Clinical Practice (GCP).

**Informed Consent Statement:** Written informed consent was given by the parents of the patient for the scientific use of clinical and molecular genetic data. An additional written consent for the use of these photographs was obtained from the parents.

**Data Availability Statement:** Data supporting reported results can be found on: <https://omim.org>, <https://www.ncbi.nlm.nih.gov/pmc>, and <https://www.genoglyphix.com> (accessed on 21 November 2022).

**Acknowledgments:** We acknowledge the mother of the patient who agreed to the scientific use of clinical and molecular genetic data and gave additional clinical information used in this publication. We also acknowledge Johannes Lemke and Harald Gaspar for initial and last medical genetics examinations, respectively.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. McKusick, V.A. Mendelian Inheritance in Man and its online version, OMIM. *Am. J. Hum. Genet.* **2007**, *80*, 588–604. [[CrossRef](#)] [[PubMed](#)]
2. Morley, T.J.; Han, L.; Castro, V.M.; Morra, J.; Perlis, R.H.; Cox, N.J.; Bastarache, L.; Ruderfer, D.M. Phenotypic signatures in clinical data enable systematic identification of patients for genetic testing. *Nat. Med.* **2021**, *27*, 1097–1104. [[CrossRef](#)] [[PubMed](#)]

3. Tzschach, A.; Graul-Neumann, L.M.; Konrat, K.; Richter, R.; Ebert, G.; Ullmann, R.; Neitzel, H. Interstitial deletion 2p11.2-p12: Report of a patient with mental retardation and review of the literature. *Am. J. Med. Genet. Part A* **2009**, *149*, 242–245. [[CrossRef](#)] [[PubMed](#)]
4. Writzl, K.; Lovrecić, L.; Peterlin, B. Interstitial deletion 2p11.2-p12: Further delineation. *Am. J. Med. Genet. Part A* **2009**, *149*, 2324–2326. [[CrossRef](#)] [[PubMed](#)]
5. Rocca, M.S.; Fabretto, A.; Faletra, F.; Carlet, O.; Skabar, A.; Gasparini, P.; Pecile, V. Contribution of SNP arrays in diagnosis of deletion 2p11.2-p12. *Gene* **2012**, *492*, 315–318. [[CrossRef](#)] [[PubMed](#)]
6. Stevens, S.J.; Blom, E.W.; Siegelae, I.T.; Smeets, E.E. A recurrent deletion syndrome at chromosome bands 2p11.2-2p12 flanked by segmental duplications at the breakpoints and including REEP1. *Eur. J. Hum. Genet.* **2015**, *23*, 543–546. [[CrossRef](#)] [[PubMed](#)]
7. Tassano, E.; Jagannathan, V.; Drögemüller, C.; Leoni, M.; Hytönen, M.K.; Severino, M.; Gimelli, S.; Cuoco, C.; Di Rocco, M.; Sanio, K.; et al. Congenital aural atresia associated with agenesis of internal carotid artery in a girl with a FOXI3 deletion. *Am. J. Med. Genet. Part A* **2015**, *167*, 537–544. [[CrossRef](#)]
8. Silipigni, R.; Cattaneo, E.; Baccarin, M.; Fumagalli, M.; Bedeschi, M.F. Rare interstitial deletion of chromosome 2p11.2p12. Report of a new patient with developmental delay and unusual clinical features. *Eur. J. Med. Genet.* **2016**, *59*, 39–42. [[CrossRef](#)]
9. Lahbib, S.; Leblond, C.S.; Hamza, M.; Regnault, B.; Lemée, L.; Mathieu, A.; Jaouadi, H.; Mkaouar, R.; Youssef-Turki, I.B.; Belhadj, A.; et al. Homozygous 2p11.2 deletion supports the implication of ELMOD3 in hearing loss and reveals the potential association of CAPG with ASD/ID etiology. *J. Appl. Genet.* **2019**, *60*, 49–56. [[CrossRef](#)]
10. Baviera-Muñoz, R.; Martínez-Rubio, D.; Sastre-Bataller, I.; Campins-Romeu, M.; Losada-López, M.; Pérez-García, J.; Novella-Maestre, E.; Martínez-Torres, I.; Espinós, C. A 3.9-Mb Deletion on 2p11.2 Comprising the REEP1 Gene Causes Early-Onset Atypical Parkinsonism. *Neurol. Genet.* **2021**, *7*, e642. [[CrossRef](#)]
11. Weaver, K.N.; Watt, K.E.; Hufnagel, R.B.; Navajas Acedo, J.; Linscott, L.L.; Sund, K.L.; Bender, P.L.; König, R.; Lourenco, C.M.; Hehr, U.; et al. Acrofacial Dysostosis, Cincinnati Type, a Mandibulofacial Dysostosis Syndrome with Limb Anomalies, Is Caused by POLR1A Dysfunction. *Am. J. Hum. Genet.* **2015**, *96*, 765–774. [[CrossRef](#)] [[PubMed](#)]
12. Smallwood, K.; Watt, K.E.N.; Ide, S.; Baltrunaite, K.; Brunswick, C.; Inskeep, K.; Capannari, C.; Adam, M.P.; Begtrup, A.; Bertola, D.R.; et al. POLR1A variants underlie phenotypic heterogeneity in craniofacial, neural, and cardiac anomalies. *Am. J. Hum. Genet.* **2023**, *110*, 809–825. [[CrossRef](#)] [[PubMed](#)]
13. Jaworek, T.J.; Richard, E.M.; Ivanova, A.A.; Giese, A.P.; Choo, D.I.; Khan, S.N.; Riazuddin, S.; Kahn, R.A.; Riazuddin, S. An alteration in ELMOD3, an Arl2 GTPase-activating protein, is associated with hearing impairment in humans. *PLoS Genet.* **2013**, *9*, e1003774. [[CrossRef](#)] [[PubMed](#)]
14. Li, W.; Sun, J.; Ling, J.; Li, J.; He, C.; Liu, Y.; Chen, H.; Men, M.; Niu, Z.; Deng, Y.; et al. ELMOD3, a novel causative gene, associated with human autosomal dominant nonsyndromic and progressive hearing loss. *Hum. Genet.* **2018**, *137*, 329–342. [[CrossRef](#)] [[PubMed](#)]
15. Li, W.; Feng, Y.; Chen, A.; Li, T.; Huang, S.; Liu, J.; Liu, X.; Liu, Y.; Gao, J.; Yan, D.; et al. Elmod3 knockout leads to progressive hearing loss and abnormalities in cochlear hair cell stereocilia. *Hum. Mol. Genet.* **2019**, *28*, 4103–4112. [[CrossRef](#)] [[PubMed](#)]
16. Liu, X.; Wen, J.; Liu, X.; Chen, A.; Li, S.; Liu, J.; Sun, J.; Gong, W.; Kang, X.; Feng, Z.; et al. Gene regulation analysis of patient-derived iPSCs and its CRISPR-corrected control provides a new tool for studying perturbations of ELMOD3 c.512A>G mutation during the development of inherited hearing loss. *PLoS ONE* **2023**, *18*, e0288640. [[CrossRef](#)] [[PubMed](#)]
17. Mao, K.; Borel, C.; Ansar, M.; Jolly, A.; Makrythanasis, P.; Froehlich, C.; Iwaszkiewicz, J.; Wang, B.; Xu, X.; Li, Q.; et al. FOXI3 pathogenic variants cause one form of craniofacial microsomia. *Nat. Commun.* **2023**, *14*, 2026. [[CrossRef](#)]
18. Quiat, D.; Timberlake, A.T.; Curran, J.J.; Cunningham, M.L.; McDonough, B.; Artunduaga, M.A.; DePalma, S.R.; Duenas-Roque, M.M.; Gorham, J.M.; Gustafson, J.A.; et al. Damaging variants in FOXI3 cause microtia and craniofacial microsomia. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **2023**, *25*, 143–150. [[CrossRef](#)]
19. Züchner, S.; Wang, G.; Tran-Viet, K.N.; Nance, M.A.; Gaskell, P.C.; Vance, J.M.; Ashley-Koch, A.E.; Pericak-Vance, M.A. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. *Am. J. Hum. Genet.* **2006**, *79*, 365–369. [[CrossRef](#)]
20. Beetz, C.; Pieber, T.R.; Hertel, N.; Schabhüttl, M.; Fischer, C.; Trajanoski, S.; Graf, E.; Keiner, S.; Kurth, I.; Wieland, T.; et al. Exome sequencing identifies a REEP1 mutation involved in distal hereditary motor neuropathy type V. *Am. J. Hum. Genet.* **2012**, *91*, 139–145. [[CrossRef](#)]
21. Beetz, C.; Schüle, R.; Deconinck, T.; Tran-Viet, K.N.; Zhu, H.; Kremer, B.P.; Frints, S.G.; van Zelst-Stams, W.A.; Byrne, P.; Otto, S.; et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. *Brain* **2008**, *131*, 1078–1086. [[CrossRef](#)] [[PubMed](#)]
22. de Bot, S.T.; van de Warrenburg, B.P.; Kremer, H.P.; Willemsen, M.A. Child neurology: Hereditary spastic paraplegia in children. *Neurology* **2010**, *75*, e75–e79. [[CrossRef](#)] [[PubMed](#)]
23. Toft, A.; Birk, S.; Ballegaard, M.; Dunø, M.; Hjeremind, L.E.; Nielsen, J.E.; Svenstrup, K. Peripheral neuropathy in hereditary spastic paraplegia caused by REEP1 variants. *J. Neurol.* **2019**, *266*, 735–744. [[CrossRef](#)] [[PubMed](#)]
24. Zhang, X.; Abreu, J.G.; Yokota, C.; MacDonald, B.T.; Singh, S.; Coburn, K.L.; Cheong, S.M.; Zhang, M.M.; Ye, Q.Z.; Hang, H.C.; et al. Tiki1 is required for head formation via Wnt cleavage-oxidation and inactivation. *Cell* **2012**, *149*, 1565–1577. [[CrossRef](#)] [[PubMed](#)]

25. Mao, X.; An, Q.; Xi, H.; Yang, X.J.; Zhang, X.; Yuan, S.; Wang, J.; Hu, Y.; Liu, Q.; Fan, G. Single-Cell RNA Sequencing of hESC-Derived 3D Retinal Organoids Reveals Novel Genes Regulating RPC Commitment in Early Human Retinogenesis. *Stem Cell Rep.* **2019**, *13*, 747–760. [[CrossRef](#)] [[PubMed](#)]
26. Moise, A.R.; Lobo, G.P.; Erokwu, B.; Wilson, D.L.; Peck, D.; Alvarez, S.; Domínguez, M.; Alvarez, R.; Flask, C.A.; de Lera, A.R.; et al. Increased adiposity in the retinol saturase-knockout mouse. *FASEB J.* **2010**, *24*, 1261–1270. [[CrossRef](#)] [[PubMed](#)]
27. Vazquez-Chona, F.R.; Khan, A.N.; Chan, C.K.; Moore, A.N.; Dash, P.K.; Hernandez, M.R.; Lu, L.; Chesler, E.J.; Manly, K.F.; Williams, R.W.; et al. Genetic networks controlling retinal injury. *Mol. Vis.* **2005**, *11*, 958–970.
28. Okubo, Y.; Masuyama, R.; Iwanaga, A.; Koike, Y.; Kuwatsuka, Y.; Ogi, T.; Yamamoto, Y.; Endo, Y.; Tamura, H.; Utani, A. Calcification in dermal fibroblasts from a patient with GGCX syndrome accompanied by upregulation of osteogenic molecules. *PLoS ONE* **2017**, *12*, e0177375. [[CrossRef](#)]
29. Diñeiro, M.; Capín, R.; Cifuentes, G.; Fernández-Vega, B.; Villota, E.; Otero, A.; Santiago, A.; Pruneda, P.C.; Castillo, D.; Viejo-Díaz, M.; et al. Comprehensive genomic diagnosis of inherited retinal and optical nerve disorders reveals hidden syndromes and personalized therapeutic options. *Acta Ophthalmol.* **2020**, *98*, e1034–e1048. [[CrossRef](#)]
30. Borna, N.N.; Kishita, Y.; Kohda, M.; Lim, S.C.; Shimura, M.; Wu, Y.; Mogushi, K.; Yatsuka, Y.; Harashima, H.; Hisatomi, Y.; et al. Mitochondrial ribosomal protein PTC3 mutations cause oxidative phosphorylation defects with Leigh syndrome. *Neurogenetics* **2019**, *20*, 9–25. [[CrossRef](#)]
31. Huck, J.H.; Verhoeven, N.M.; Struys, E.A.; Salomons, G.S.; Jakobs, C.; van der Knaap, M.S. Ribose-5-phosphate isomerase deficiency: New inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy. *Am. J. Hum. Genet.* **2004**, *74*, 745–751. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.